EC approves Polpharma Biologics’ Tyruko biosimilar for MS
Polpharma Biologics, an international biotech company focused on developing and manufacturing biosimilars, has received approval from the European Commission for Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. Tyruko was developed by Polpharma Biologics and will be commercialized by its collaboration partner Sandoz.
